Ŀ¼ hOIg7=v
ͬ¼ÃÒ½¿Æ´óѧ1999ÄêÄÚ¿ÆÑ§ÊÔÌâ V0#E7u`4
ͬ¼ÃÒ½¿Æ´óѧ2000ÄêÄÚ¿ÆÑ§ÊÔÌâ Qd?S~3XT
ÄϾ©Ò½¿Æ´ó99ÄêÉñ¾²¡Ñ§ \
sz ](X
ºÓ±±Ò½¿Æ´ó2001ÄêÉñ¾²¡Ñ§ÊÔÌâ l`j@QP
2005ÄêÖÐɽҽ´ó²¡ÉúÊÔÌâ n|QA\,=
ÄÏ·½Ò½¿Æ´óѧ2005ÃâÒßÌâ )kKeA
2005ÄêкͲ©Ê¿ÃâÒßÊÔÌ⣨רҵ»ù´¡£© vKkvB;F41
2005Äêͬ¼Ã²©Ê¿ÈëѧÕï¶ÏÌâ rX`fjS*C
2005É϶þÒ½²©Ê¿·Ö×ÓÉúÎïѧ£¨×¨Òµ»ù´¡£© bhZ5-wo4%
2005ÄêÉ϶þÒ½²©Ê¿Éú»¯¿¼Ìâ wlP%
U
ÄÏ·½Ò½¿Æ´óѧ2005ϸ°ûÉúβ©ÊÔÌâ +}-cvM/*
2005Ä긴µ©´óѧ·ÅÁÆ¿¼²©ÊÔÌâ TUp%Cx
ͬ¼ÃÒ½¿ÆÔºÀúÄêÉñ¾½âÆÊѧÊÔÌâ D2:ShyYAS
2004ÄêÊ×Ò½Éñ¾½âÆÊÌâ IeIv k55
µÚËľüÒ½´óѧÀúÄêÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ `soQp2h-
1_n5:
¾ßÌå¼ûÏÂ: ~~ty9;KYL
T?-K}PUcQ
ͬ¼ÃÒ½¿Æ´óѧ1999ÄêÄÚ¿ÆÑ§ÊÔÌâ fX&g. fH
Ò»¡¢ Ãû´Ê½âÊÍ£º1¡¢¾üÍžú²¡Àú¡¢¸ßѪѹÄÔ²¡3¡¢Î¸ÃÚËØÁö4¡¢Õù½øÐÔÉöÑ×5¡¢PhȾɫÌå6¡¢Grares²¡ K<u~[^R
¶þ¡¢Ìî¿Õ£º1¡¢ÂýÐÔºôÎüË¥½ßIÐ͵ÄÑªÆø·ÖÎöÌØµã£¨1£© £¬IIÐ͵ÄÑªÆø·ÖÎöÌØµã£¨2£© ¡£ 2¡¢ÐÄÔà´«µ¼ÒõÖͰüÀ¨£¨1£© £¨2£© £¨3£© £¨4£© ¡£ 3¡¢Ä¿Ç°ÒÖÖÆÎ¸Ëá·ÖÃÚ×îÇ¿µÄÒ»ÀàÒ©ÊÇ£¨1£© 4¡¢½áºËÐÔ¸¹Ä¤Ñ××î³£¼ûµÄ²¢·¢Ö¢ÊÇ£¨1£© 5¡¢¼±ÐÔÉö¹¦ÄÜË¥½ßÁÙ´²Ò»°ã·ÖΪ£¨1£© £¨2£© £¨3£© ÈýÆÚ¡£ 6¡¢ÓлúÁ×ũҩÖж¾µÄ»úÀíÖ÷ÒªÊÇÒÖÖÆÁË£¨1£© £»Ò»Ñõ»¯Ì¼Öж¾Ê±£¬»úÌå¶ÔȱÑõ×îÃô¸ÐµÄÆ÷¹ÙÊÇ£¨2£© £¨3£© ¡£ 7¡¢¸ù¾Ý²¡ÒòºÍ·¢²¡»úÖÆ£¬½«Æ¶Ñª·ÖΪ£¨1£© £¨2£© £¨3£© ÈýÀà¡£ 8¡¢¼±ÐÔ°×Ѫ²¡µÄMIC·ÖÐÍÊÇÖ¸£¨1£© £¨2£© £¨3£© µÄ·ÖÐÍ¡£9¡¢¿Ú·þ½µÌÇÒ©Îï·ÖΪ£¨1£© ºÍ£¨2£© Á½Àà¡£ 10¡¢Ð¡¼ÁÁ¿µØÈûÃ×ËÉÒÖÖÆÊÔÑéÖ÷ÒªÓÃÓÚ£¨1£© Ó루2£© µÄ¼ø±ðÕï¶Ï£»´ó¼ÁÁ¿µØÈûÃ×ËÉÒÖÖÆÊÔÑéÖ÷ÒªÓÃÓÚ£¨3£© ºÍ£¨4£© µÄ¼ø±ð¡£ =D 5!Xq'|
Èý¡¢ ¼ò´ðÌ⣺1¡¢¼òÊöÂýÐÔÖ§Æø¹ÜÑ×µÄÕï¶Ï±ê×¼¡£2¡¢ºÎΪǰ¸ººÉ¡¢ºó¸ººÉ£¿3¡¢Ô·¢ÐԸΰ©×ÛºÏÕ÷ÓÐÄÄЩ±íÏÖ£¿ xtXK3[s
"1ZVuI
ͬ¼ÃÒ½¿Æ´óѧ2000ÄêÄÚ¿ÆÑ§ÊÔÌâ #Pq6q.UB
Ò»¡¢ Ãû´Ê½âÊÍ£º1¡¢ÕÅÁ¦ÐÔÆøÐØ2¡¢ÐÄÁ¦Ë¥½ß3¡¢Grey-TurnerÕ÷4¡¢IgAÉö²¡5¡¢AureСÌå6¡¢Ï¯ºº×ÛºÏÕ÷ I]d?F:cdX
¶þ¡¢Ìî¿Õ£º1¡¢ÁÙ´²Õï¶Ï·Î½áºËʱ£¬Ó¦°üÀ¨ ¡¢ ¡¢ ¡¢ Ëĸö²¿·Ö¡£ 2¡¢Ñ󵨻ÆÀàÒ©ÎïËØÐÔ·´Ó¦µÄÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ ¡£ 3¡¢¸ÎÓ²»¯ÉÏÏû»¯µÀ³öѪµÄ²¡ÒòÓÐ ¡¢ ¡¢ ¡£ 4¡¢ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨DIC£©µÄÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ ¡¢ ¡£5¡¢ÈÜѪÐÔÆ¶ÑªÊ±ºìϸ°û´ú³¥ÐÔÔöÉúµÄ±íÏÖÓÐ ¡¢ ¡¢ ¡£ 6¡¢ËáÈÜѪÊÔÑ飨HamÊÔÑ飩ÑôÐÔ¿ÉÒÔÕï¶Ï £¬ÓÃÓÚÕï¶Ï²¢¼ø±ðѪÓѲ¡ÀàÐ͵ÄʵÑéÊÒ¼ì²éÊÇ ¡£ 7¡¢ÉÙÄòÊÇÖ¸ £¬ÎÞÄòÊÇÖ¸ 8¡¢Éö×ÛºÏÕ÷µÄ²¢·¢Ö¢ÓÐ ¡¢ ¡¢ ¡¢ ¡£ 9¡¢¼±¿¯ÐÔÉöÑ׵IJ¡ÀíÑÕ÷Ϊ ¡¢ÔçÆÚΪ £¬ºóÆÚΪ ¡£ 10¡¢¼±ÐÔÓлúÁ×Öж¾Ö÷ÒªÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ Èý¸ö·½Ãæ¡£ 11¡¢¿¹¼××´ÏÙÒ©Îï³£ÓõÄÊÇ À࣬Æä×÷ÓûúÖÆÊÇ ºÍ ¡£ 12¡¢ÌÇÄò²¡ÍªÖ¢ËáÖж¾²¹¼îÖ¸Õ÷Ϊ »ò ¡£ 13¡¢ÄâÅųýÊȸõϸ°ûÁöÒýÆðµÄ¸ßѪѹ£¬Ó¦×ö ʵÑéÊÒ¼ì²é°ïÖúÕï¶Ï¡£ W5RZsS]
Èý¡¢¼ò´ðÌ⣺1¡¢¼òÊö½áºËÐÔÐØÄ¤Ñ×ÐØË®ÌØµã¡£ 2¡¢¼òÊöÕó·¢ÐÔÊÒÉÏÐÔÐ͝¹ýËÙµÄÖÎÁÆÔÔò¡£ 3¡¢¼òÊö¸ÎÐÔÄÔ²¡µÄÖ÷ÒªÕï¶ÏÒÀ¾Ý¡£ &G+
:t)|S
^DR`!.ttr
ÄϾ©Ò½¿Æ´ó99ÄêÉñ¾²¡Ñ§ >P ygUY
d
1.¡¢ÊÔÊö²¡¶¾ÐÔÄÔÑ׵ıíÏÖ£¿ ¶þ¡¢ÊÔÊöСÄÔ²¡±äµÄÁÙ´²±íÏÖ£¿ Èý¡¢ÊÔÊöÄÔðÞµÄÁÙ´²±íÏÖ£¿ 3¡¢Ãû´Ê½âÊÍ 1.¸Ð¾õÐÔʧÓï 2¡¢±È¸¥×ÛºÏÕ÷ |Gb~[6u
sQY0Xys<4
ºÓ±±Ò½¿Æ´ó2001ÄêÉñ¾²¡Ñ§ÊÔÌâ 8GT{vW9
Ò».ÖÜΧÉñ¾¼²²¡»ù±¾²¡Àí±ä»¯Óм¸ÖÖ?²¢¼ÓÒÔ˵Ã÷ ¶þ.¼òÊöÖëÍøÄ¤ÏÂÇ»³öѪµÄÖ¢×´,ÌåÕ÷ºÍÖÎÁÆÔÔò,²¢¾Ù³öÈýÖÖ³£¼û²¡Òò? Èý¡¢ÖØÖ¢¼¡ÎÞÁ¦·¢²¡ÔÀí?ºÎν¼¡ÎÞÁ¦Î£Ïó¼°µ¨¼îÄÜΣÏó?Èç·¢ÉúÉÏÊöÁ½ÖÖΣÏóÈçºÎ´¦Àí? ËÄ¡¢ºÎνÄÔĤ´Ì¼¤Ö¢?¾Ù³ö³ýÄÔĤÑ×Ö¢ÒÔÍâµÄÈýÖÖ¼²²¡? Îå.¼òÊöÇÅÄÔСÄÔ½Å×ÛºÏÖ¢ÁÙ´²±íÏÖ?Áù¡¢ºÎν±ÕËø×ÛºÏÖ¢? Æß.ÉÏʧñ¼ÑªË¨Ðγɲ¡Òò¼°ÁÙ´²±íÏÖ? VDv>I 2%
MXY!N/
2005ÄêÖÐɽҽ´ó²¡ÉúÊÔÌ⣺ E>}3MfL
Ò»£¬Ãû´Ê½âÊÍ£º ?~~,?Uxw!
1¡£·ÎÐÔÄÔ²¡(Ó¢ÎÄ) (K>4^E8
2¡£·ÇÉÙÄòÐÍARF wQ9fPOm
3¡£µòÍö(Ó¢ÎÄ) |F>'7JJJ
4¡£¹ýÈÈ(Ó¢ÎÄ) xTdh/
}
¶þ£¬ÎÊ´ðÌâ eZRu{`AF*
1¡£ÊÔÊöÓ¦¼¤·´Ó¦Ê±ÏÂÇðÄÔ-´¹Ìå-ÉöÉÏÏÙ¼¤»îµÄÉúÎïѧЧӦ(ÀûÓë±Ö) )G9,5[
2¡£Êö¸ÎÐÔÄÔ²¡Ê±°±»ùËáʧºâµÄÔÒòºÍÒýÆð¸Î»èÃԵĻúÖÆ¡£ 7ZpU -':
3¡£ÎªºÎ¸ïÀ¼ÊÏÒõÐÔ¾ú¸ÐȾÒ×ÒýÆðDIC "V7 &@3
4¡£ÍíÆÚÐÝ¿ËÒýÆðºôÎüË¥½ßµÄ»úÖÆ ).> O6A4:C
+t;j5\HS
ÄÏ·½Ò½¿Æ´óѧ2005ÃâÒßÌâ XiUae{j`
1ÒìÊÈÐÔ¿¹Ô Ĥ¹¥»÷¸´ºÏÌå ·Ö×ÓÄ£Äâ ϸ°ûÒò×Ó ¹²´Ì¼¤Òò×Ó Õ³¸½·Ö×Ó Ä£Ê½Ê¶±ðÊÜÌå SmIg HLA Westenbloting Ha/-v?E
2\ÃâÒßµÄÏÖ´ú¸ÅÄîÊÇʲô£¿ÈçºÎÀí½âËüµÄË«ÖØÐÔ£¿ W6uz
G
3.ϸ°ûÒò×ӵĹ²Í¬ÌØÕ÷£¿ÓÐÄÄЩÖ÷ÒªµÄ ÉúÎïÑ§ÌØÕ÷£¿ {= l9{K`~
4.CD4+ Th1¡¢Th2ÔÚÃâÒßÓ¦´ðÖеÄ×÷Óã¿ p\/;^c`7
5.ÃâÒßÄÍÊÜ¡¢ÃâÒßÒÖÖÆºÍÃâÒßȱÏݵÄÒìͬµã£¡ 5?4jD]Z
6.¾ö¶¨¿¹ÔÃâÒßÔÐÔµÄÒòËØÓÐÄÄЩ£¿Êµ¼ùÖÐÈçºÎÖÆ±¸¸ßЧ¼ÛµÄ¿¹Ì壿 -*C+z!?BP
7.¾ÙÀý˵Ã÷È˹¤ÃâÒߵķ½·¨£¬¼òÊöÆäÔÚ¼²²¡·ÀÖÎÖеÄ×÷Óú͵ØÎ»£¿ x AR9* <-
8.¿¹¸ÐȾÃâÒßÖУ¬ÌìÈ»ÃâÒßÓë»ñµÃÐÔÃâÒßÊÇÈçºÎÅäºÏ¡¢Ï໥²¹³ä£¿ \*$''`b)j
,Tc598D
2005ÄêкͲ©Ê¿ÃâÒßÊÔÌ⣨רҵ»ù´¡£© Qa=v }d-O
µÚÒ»²¿·Ö¸÷רҵ¹«¹²ÊÔÌâ Õ¼70·Ö veh?oJi@
1 Åж϶Դí ;3WVrYe
2 Ìî¿Õ p_2-(n@
µ¥Á´¿¹ÌåÊÇ£¨ £©ºÍ£¨ £©Á¬½Ó£¬ÊôÓÚ£¨ £©¿¹Ìå ,XNz.+Ov
ÃâÒß¼àÊÓ¹¦ÄܵÍÏÂÒ×·¢Éú£¨ £© r%~/y
ÇáÁ´·ÖΪ£¨ £©£¨ £©ÐÍ Zb=H\#T
²úÉúͬÖÖÐÍ¿¹ÌåÓ㨠£©¶¯ÎïÃâÒß OfGMeN6
¿¹Ìå¶àÑùÐԵIJúÉúÔÒò£¨ £©£¨ £©£¨ £© BliL1"".
ÃâÒßÓ¦´ðµÄ²úÉú½×¶Î£¨ £©£¨ £©£¨ £© k~ZE4^dM
3 Ñ¡Ôñ d@-bt s&3
4 Ãû´Ê½âÊÍ10·Ö h*9s^`9)
LAK £¬ Ö×ÁöÏà¹Ø¿¹Ô£¬TCR£¬ÁöÃ磬J chain¡£ VdV18-ea
5 ¼ò´ðÌâ8·Ö yb:Xjg7
²¹ÌåµÄÉúÎïѧ»îÐÔ <Sx-Ca7
TS{ycGY
µÚ¶þ²¿·ÖΪ¸÷¸öרҵµÄÊÔÌâ30·Ö 0R%R2p'wG
Éö²¡×¨Òµ±Ø´ðÌâ Ec^x
1 ÂýÐÔÒÆÖ²ÅųâµÄ¸ÅÄӰÏìÒòËØ£¬·ÀÖη½·¨15·Ö !yQ# E2/A
2 ÀÇ´¯ÉöÑ׵ķ¢²¡»úÀí15·Ö ,KHebv!
OZ6gu$
n*
·çʪ²¡×¨Òµ±Ø´ðÌâ q'%-8t
1ÊɾúÌ忹Ìå¿âµÄ¹¹½¨ 2#bpWk 9
2 ÃâÒßÇòµ°°×¹¦ÄÜÇøµÄ×÷Óà 3"Y
|RSy
3 ÍüÁË 5[_|+
Z2,[-8,Kx
¸¾¿Æ±Ø´ðÌâ E6
2{sA^
ճĤÃâÒßϵͳ t_PAXj
U!rhj&n
2005Äêͬ¼Ã²©Ê¿ÈëѧÕï¶ÏÌâ WZa?
Xb
Ò» Ãû´Ê½âÊÍ£¨3`X 5£© i+)9ItZr
1. PCR spE(s%dgL
2. Urin Osmol V9tG2mLf>
3. Velcro†ªÒô 9K\A4F}
4. S2¹Ì¶¨·ÖÁÑÒô G:HPd.ay
5. Standard bicarbonate 7n,*3;I
#3l&N4/
¶þ ÎÊ´ðÌâ 8%qHy1
1. ²»Í¬Çé¿öϸ¹±Ú¾²ÂöÇúÕŵķ½Ïò¼°±æ±ð¸¹±Ú¾²ÂöÇúÕÅÀ´Ô´µÄ·½·¨¡£ H]7MN Y
2. ÊæÕÅÆÚ±¼ÂíÂɵÄÌýÕïÌØµã¼°ÆäÓëÉúÀíÐÔµÚÈýÐÄÒôµÄÇø±ð¡£ )c:i'L
3. ¼±ÐÔǰ±ÚÐĹ£ÐĵçͼµÄÑݱä¹ý³Ì¼°ÌØÕ÷¡£ f,ajo
4. ²¡Àí·´ÉäµÄ¸ÅÄî¼°ÄÚÈÝ¡£ ^Gc#D:zU
5. LDLÖÂASµÄ»úÖÆ¡£ }i7Gv K<[:
6. Å®£¬30Ë꣬·¢ÈÈ¿ÈËÔ¡¢¹Ø½ÚÍ´Ò»¸öÔ¡£Ìå¼ì£º38¶È£¬Ë«Ã沿µûÐκìɫƤÕ˫·ÎºôÎüÒô¼õÈõ£¬ÐØÆ¬Ê¾Ë«²àÐØÇ»»ýÒº£¬ÄòPro +++,¹ÜÐÍÄò¡£ "Cz8nG
1£©×î¿ÉÄܵÄÕï¶Ï Q{ibH=^
2£©ÎªÃ÷È·Õï¶ÏÊ×ѡʵÑéÊÒ¼ì²é %Y7\0q~Z
3£©¼ÙÉèÕï¶Ï³ÉÁ¢£¬¶ÔÕï¶Ï×î¾ß¼ÛÖµµÄʵÑéÊÒ½á¹û¡£ {=5Wi|
7. ÄУ¬27Ë꣬ÑáÓͰ鷦Á¦£¬ÄɲƤ·ô»ÆÈ¾Ò»ÖÜ£¬°éºÚ±ãÄòÉÙ£¬ÒâʶÕϰÁ½Ìì¡£²éÌ壺ÉñÖ¾²»Ç壬Ƥ·ô¹®Ä¤»ÆÈ¾£¬È«ÉíÉ¢ÔÚðö°ß£¬Íܸ¹£¬³¦ÃùÒô¼õÈõ¡£ UQmdm$.
1£©×î¿ÉÄܵÄÕï¶Ï 7$8YBcZ6
2£©´ËʱÊ×Ñ¡½øÐиÎÔà´¥ÕïµÄ·½·¨¼°¼ì²é½á¹û h/7m.p]
3£©×îӦѡÔñµÄ¸Î¹¦Äܼì²éÏîÄ¿¡£ Z=P]U
D
8. ÄУ¬60Ë꣬·´¸´¿ÈËÔ¿È̵´Æø20Ä꣬ÔÙ·¢Á½ÖÜסԺÖÎÁÆ£¬¾¿¹¸ÐȾ¡¢½â¾·¡¢Æ½´ÖÎÁÆÓÐËù»º½â£¬×òÍíÍ»·¢ÐØÃÆ£¬ºôÎüÀ§ÄÑ¡£Ìå¼ì£º¶Ë×øÎ»£¬¿Ú´½·¢ç¤¡£Çë·ÖÎö .Du-~N4\
1£©¸Ã²¡ÈË×îÓпÉÄܵÄÕï¶Ï
}pOem}
2£©È·ÕïËùÐèµÄÊ×Ñ¡¼ì²é T)ZO+}
3£©¼ÙÉè¸ÃÕï¶Ï³ÉÁ¢£¬Æä×î¾ßÕï¶Ï¼ÛÖµµÄÑôÐÔÌåÕ÷¡£ x]~{#pH@<
W$g<nhLK
2005É϶þÒ½²©Ê¿·Ö×ÓÉúÎïѧ£¨×¨Òµ»ù´¡£© E;Akm':
ÈýÁ´DNA j06q3N"
ת»ùÒò¶¯Îï cO]_5@#f'8
IP3 |yqL0x0\l
Ãû´Ê½âÊÍ D"x;/I
±í´ïÐòÁбêÇ© oa4{s&db-
»îÐÔëÄ bi^[Eh
Äæ×ªÂ¼Ã¸ /i'dhiG
ÖÎÁÆÐÔ¿Ë¡ `Bw>0%.
¶ËÁ£Ã¸ l :e&w(1H
ÔÓ½»×èÖÍ·Òë xc4g`Xi
run off transcription (!^i6z0Sp
µòÍöµ°°×
q%g!TFMg
ÎÊ´ð U3R;'80 f
DNA¸´ÖƵĹý³Ì 5G
>{*K/
ºËµ°°×ÌåÔÚµ°°×ºÏ³É×÷Óà ULqFJ*nla
Äý½º¹ýÂ˲ãÎöµÄÓ¦ÓýøÕ¹
%25GplMT
(gdi2
2005ÄêÉ϶þÒ½²©Ê¿Éú»¯¿¼Ìâ .uo9VL<
Ãû´Ê½âÊÍ F$tshe(
Ѫ½¬¹¦ÄÜø t)!(s,;T
Gµ°°× %T~3xQ
·Ö×Ó°é i?{cB!7
LCAT hH&A1vUv
¼ò´ð %QYH]DR
¸ÎÔàËðÉË·²µÇ°×Ë«ÑôÐÔ»úÖÆ Mj9Mv<io
ÎÊ´ðÌâ DJ zJ$Q
»ùÒòÕï¶ÏµÄ·½·¨£¬¾ÙÀý HLlp+;CF><
ѪNH3µÄÀ´Ô´È¥Â· tsY
BZaH
TRNA¶þ¼¶½á¹¹Ìصã×÷Óà !HV<2q()
ΪʲôÌÇÉãÈ¡¹ý¶à»á·ÊÅÖ &nKb<o
ÐźŴ«µ¼Í¨Â· ^k*h
6Á×ËáÆÏÌÑÌÇ£¬¼ºÌǼ¤Ã¸£¬±ûͪËáÔÚÎïÖÊ´úлΪÊàŦµØÎ»µÄÔÒò -:$#ko
W
DNA±àÂëÐòÁÐÒ»¸öbpµÄÍ»±äÓÐʲôºó¹û£¿¾ÙÀý˵Ã÷ 9;ZaL7>
-Lo3@:2i
ÄÏ·½Ò½¿Æ´óѧ2005ϸ°ûÉúβ©ÊÔÌâ x6qQ
Y<>
1.ÊÜÌå½éµ¼µÄÄÚÍÌ×÷ÓõĹý³ÌÒÔ¼°Ìص㣿 u~]O
#v
2.ϸ°û¼äÓм¸ÖÖÁ¬½Ó·½Ê½£¬ÆäÖÐÄÇÖÖ¾ßÓÐϸ°ûͨѶ×÷Óã¬ÒÔ¼°ÎªÊ²Ã´£¿ #YiphR&
3.³ÉÊì´Ù½øÒò×ÓµÄ×é³ÉÒÔ¼°ÔÚϸ°ûÖÜÆÚµ÷¿ØÖеÄ×÷Óã¿ :637MD>5lO
4.ϸ°ûÖÜÆÚµ÷¿ØµÄÑо¿·½·¨£¿ K *QRi/O
5.ÔÚ·Ö×ÓºÍϸ°ûˮƽÉ϶Ôϸ°ûË¥ÀϸÅÄî½øÐвûÊö£¿ yhuzjn
ÔºËÉúÎïDNA¾ÛºÏø3ºÍRNA¾ÛºÏøµÄÌØµã ;4%Co)Rw
s"'ns
2005Ä긴µ©´óѧ·ÅÁÆ¿¼²©ÊÔÌâ (XU(e
·ÅÉäÖÎÁÆÑ§(רҵ¿Î)
` P,-NVB
1. ÏÖ´úÖ×Áö·ÅÉäÖÎÁÆÁ÷³Ì S/2lK*F
2. ÈçºÎ±£Ö¤°ÐÇø¹´»µÄÒ»ÖÂÐÔºÍ׼ȷÐÔ Jv8JCu"eky
3.ºí°©·ÖÐͺÍÖÎÁÆÔÔò znkc@8_4
4. Ìá¸ß·ÇСϸ°û·Î°©ÁÆÐ§µÄ·ÅÉäÖÎÁƼ¼Êõ qlNB\~HCe
5. ×ÛºÏÖÎÁƵÄÖØÒªÐÔ gb^<6BYUG
Ö×Áöѧ(רҵ»ù´¡) ~_]i'ii8
1.Ãû´Ê½âÊÍ l:.q1UV
ÓÀÉú»¯ µ¥ºËÜÕËá¶à̬ÐÔ ½»½çÐÔÖ×Áö ²»µäÐÍÔöÉú HOr.(gL!
2. ÂÛÊöÌâ X
t%y>'.
2.1 ϸ°û¶ñ±ä P-_2IZiz
2.2 ¶à»ùÒòÒÅ´«²¡Ìصã 0
3?7kAI
2.3 ÒÖ°©»ùÒò¸ÅÄîºÍÒÖ°©»úÖÆ 8=-/0y9,
2.4 Î¢×ªÒÆ¸ÅÄîºÍÁÙ´²ÒâÒå @TraEBJGL
2.5 µòÍöÆÕ±éÉúÎïѧÒâÒå `gSJEq
p6&6^v\
2001ͬ¼ÃÒ½¿ÆÔºÉñ¾½âÆÊѧÊÔÌâ bCg)PJuB
Yma-$ytp
Ò»Ãû½â£º1´óÄÔ¶¯Âö»· 2Ö²ÎïÉñ¾ÏµÍ³ 3 internal capsule 4 choroid plexus KLpFW}
m:W+s4!E
¶þÎÊ´ð£º1¡£´©¾º£Ãàñ¼µÄÄÔÉñ¾ÓÐÄÄЩ£¿·Ö±ð¼òÊöËüÃǵķֲ¼
AT
-
sHPK8Wsg
2¡£¼¹ËèÄÚ±¡Êø£¬Ð¨Êø£¬¼¹ËèÇðÄÔ²àÊøºÍƤÖʼ¹ËèÊøµÄλÖã¬ÆðÖ¹ºÍ¹¦ÄÜ 9&"wfN N
,R7RXpP7t
3¡£ÄÔÉñ¾£¨Â²¿£©µÄ¸±½»¸ÐÉñ¾½ÚÓÐÄÄЩ£¿Æä½ÚǰÏËά·Ö±ðÆð×Ժ䦣¿½ÚºóÏËά·Ö²¼µ½ÄÄÀï¡£
aE2Yl
q71V]!
4ij»¼ÕßÍ·²¿ÓÒ²àò¨ÇøÊÜËðÉ˺óÁ½Ð¡Ê±×óÓÒ£¬Í»È»»èµ¹£¬ËÍÒ½Ôº¼ì²é·¢ÏÖ£º£¨1£©ÓÒÍ«¿×É¢´ó£¬Ö±½ÓºÍ¼ä½Ó¶Ô¹â·´ÉäÏûʧ£¬ÓÒÑÛíúÏ´¹£»£¨2£©×óÉÏ£¬ÏÂÖ«²»Äܻ£»£¨3£©×óÏ¥·´É俺½ø£¬×ãèÏ·´ÉäÑôÐÔ¡£Õï¶ÏΪӲĤÍâѪÖײ¢·¢Ð¡ÄÔÄ»ÁÑ¿×ðÞ¡£ÊÔ·ÖÎö£º£¨1£©ËðÉËÁËʲôѪ¹Ü£¿¸ÃѪ¹ÜÆðÓں䦣¿¾ºÎ´¦È룿£¨2£©ÖðÒ»½âÊͳöÏÖÉÏÊö3×éÖ¢×´£¬ÌåÕ÷µÄÔÒò¡£ bNG7A[|B
9!,f4&G`
2000 k0IztFyj:R
wl0 i3)e:
Ò»Ãû½â bcUa'ZfN<
1ÄÔÆÁÕÏ 2×¶ÌåÍâϵ 3 Ö²ÎïÉñ¾Ïµ 4ÄÚÄÒ +EvY-mwfQ
hr?0RPp}
¶þÎÊ´ð >f:OU,"
1¡£ ëè¹Ç¾±¹ÇÕÛÒ×ËðÉËÄÄÌõÉñ¾£¬³öÏÖÄÄЩ֢״£¬ÌåÕ÷£¬ÎªÊ²Ã´£¿ CPLsSv5
l:14uWu|
2¡£¼òÊöÄԵ͝ÂöÀ´Ô´¼°¹©Ñª·¶Î§ D"<>!]@(a
Q[&CtM
3¡£Ð¡ÄÔÄ»Çм£ðÞÓëÕí¹Ç´ó¿×ð޵ĽâÆÊѪ»ù´¡£¬»á²úÉúÄÄЩºó¹û W0LJXp-v
uC5W1LyI
4¡£ÊÔÊöƤÖʺËÊø }_h
2:^n
3z!^UA>q
1999 ]DK.4\^
|D~#9
Ò»Ãû½â *|S{%z9>
1ÎÆ×´Ìå 2°×½»Í¨Ö§ 3 ÏËÎ¬Êø 4¶¥¸ÇÇ°Çø Jzj>=jWX@
q j*77
¶þÎÊ´ð POb2U1Sj
1¡£ÊÔÊöÐØÉñ¾Ç°Ö§µÄ½Ú¶ÎÐÔºËÖØµþÐÔ <*+Y]=
f"d4HZD^
2¡£ÄÚÄÒËðÉËʱΪʲô»á³öÏÖ¡°ÈýÆ«×ÛºÏÕ÷¡±£¿ Ta)6ly7'
o(Q='kK
3¡£ÊÔÊö×µ£»ùµ×¶¯Âöµ×Ðг̣¬·ÖÖ§ºÍ·Ö²¼£¿ ty
bM3VA
;s w3MRJ
4¡£¼¹ËèÐØ7ÓÒ°ìËðÉËʱ»¼Õß»áÓÐÄÄЩ¸Ð¾õ£¬Ô˶¯Õϰ£¿¼òÊöÆäÔÒò pTE.,~-J^j
vf
h*`G$
1998 1*]@1DJt
Ò»Ãû½â Vv.q{fRvYB
1¡£»ùµ×ºË 2¡£´óÄÔ¶¯Âö»· 3 ÄÔÊÒÂöÂç´Ô 4Ç£ÉæÐÔÍ´ 5б·½Ìå '9Xw_1B
jHM}({)-
¶þÎÊ´ð W4rh7e4
1¡£ÔÚ´óÄÔÆ¤ÖÊ»úÄܶ¨Î»ÖУ¬µÚÒ»ÇûÌå¸Ð¾õÇøÎ»Óں䦣¬ÉíÌå¸÷²¿ÔÚ´ËÇøµÄͶӰÓкÎÌØµã
oU)HxV
Ku;8Mx{
2ÉÏÏÂÔ˶¯Éñ¾ÔªËðÉ˵ÄÖ¢×´ÓëÌåÕ÷Óкβ»Í¬£¬ÎªÊ²Ã´£¿ F!&_
m95;NT1N/g
3Õë´ÌÓÒÊÖСָƤ·ô TH1Éñ¾Ö§ÅäÇøºóÍ´¾õ³å¶¯¾ºÎ;¾¶´«Èë´óÄÔ br7_P1ep
'sN
(=CQ
4ëõÉñ¾µÄ×é³É£¬Ðо¶ºÍ·Ö²¼ XFcIBWS
m|k:wuzqK
5¼¹Ëèǰ½Çϸ°ûµÄÀàÐͼ°Æä¹¦ÄÜ /rmm@
D(^ |'1
1997 ] KR\<MJK
Ò»Ãû½â 6ZwFU5)QE/
1¡£Ð¡ÄÔºË 2¡£ÄÔ¸ÉÍø×´½á¹¹ 3 ÖëÍøÄ¤Á£ 4 ÄÚ²àÇðϵ½»²æ etLA F
¶þÎÊ´ð l@nG?l #
1¡£ÊÔÊöÉàµÄÉñ¾Ö§Åä¼°Æä×÷Óà y3)R:h4AH
2¡£´¹ÌåÖ×ÁöѹÆÈÊÓ½»²æºó»¼ÕßµÄÊÓ¾õÓкÎÕϰ£¬ÎªÊ²Ã´?Çëͬʱд³öÊÓ¾õ´«µ¼¾¶Â· 6>;dJV
3ëŹÇÍâ¿Æ¾±¹ÇÕÛ£¬ëŹÇÖжιÇÕÛºÍëŹÇÄÚÉÏ÷Á¹ÇÕÛʱ£¬¸÷Ò×ËðÉËÄÇÌõÉñ¾£¬ëŹÇÍâ¿Æ¾±¹ÇÕ۵ϼÕß³£°éÓÐʲô¹¦ÄÜÕϰ *XSHzoT*
4ÁÙ´²ÉϾ¼¹ËèÖëÍøÄ¤ÏÂÇ»´©´Ì³éÈ¡ÄÔ¼¹Òº£¬³£ÔÚ3£4Ñü×µ¼¬Í»¼ä϶´ÌÈ룬Æä½âÆÊѧ»ù´¡ÊÇʲô xN]88L}Tn
a>/jW-?
1996 pxO?:B
ÎÊ´ð $XO#qOW
1¡£ÊÔÊö¹ÄË÷µÄÏËά³É·Ö£¬Ðг̷ֲ¼Ó빦ÄÜ WMXk-?v4
2£¬ÓÐÄÄЩÉñ¾·Ö²¼ÖÁÊÓÆ÷£¬Çë·Ö±ð¼òÊöËüÃǵÄÐÔÖÊ£¬·Ö²¼ºÍ¹¦ÄÜ H:&|q+K=#
3¡£Ð¡ÄÔ±âÌÒÌåλÓں䦣¬ÇëÓýâÆÊѧ֪ʶ½âÊÍСÄÔ±âÌÒÌåðÞ·¢ÉúµÄ»úÀíºÍÑÏÖØºó¹û ~pj/
_@S@x
4£¬ÊÔÊöµÚËÄÄÔÊÒµÄλÖ㬹¹³ÉºÍ½»Í¨ K/+w6d
5¡£ëè×ÜÉñ¾ËðÉ˺÷¢Óںβ¿Î»£¬ÊÜËðʧºóÓÐÄÄЩÖ÷Òª±íÏÖ£¬ÎªÊ²Ã´£¿ {Tym#
6¡£ÄÚÄÒÏ¥²¿Í¨¹ýÄÄЩ´«µ¼Êø£¬ÆäËðÉ˺óÓÐÄÄЩÖ÷Òª±íÏÖ£¬ÎªÊ²Ã´£¿ pCm |t!,
7¡£ÊÔÊöÄÚÔà´ó£¬Ð¡Éñ¾µÄÆðÔ´£¬ÁªÏµ¼°½ÚºóÏËά·Ö²¼¸Å¿ö [MVG\6Up(
K\]I@UTwq
1995 7Yrp#u1!
Ò»Ãû½â @x
z?^20N
1¡£±¾Ìå¸Ð¾õ 2¡£Éñ¾ºË 3¡£¹ÌÌåÊø 4¡£ëÝíûÌå 56R)631]p
¶þ¡£ÎÊ´ð 4 9zOhG
|
1¡£ÔÚÄԸɸ½×ÅÓм¸¶ÔÄÔÉñ¾£¬ËüÃǸ÷ÊôºÎÐÔÖÊ£¬¸÷º¬¼¸ÖÖÏËά³É·Ö£¬²¢·Ö±ðд³öËüÃÇµÄÆðʼºË»òÖÐÖ¹ºË MVpk/S%W
2¡£ÈÝÒ׺ϲ¢èãÉñ¾ËðÉ˵ÄëŹǹÇÕÛ³£·¢ÉúÔÚʲô²¿Î»£¬¸ÃÉñ¾ËðÉ˺óÓкÎÔ˶¯Óë¸Ð¾õÕϰ£¬ÎªÊ²Ã´ zxt&oT0Q
3¡£½»¸ÐÉñ¾Ó븱½»¸ÐÉñ¾µÄÖ÷񻂿±ðÔÚÄÄÀï NFQR
4ÓҲදÑÛÉñ¾ÊÜËðÉËʱ£¬ÓÒÑÛÍ«¿×Ö±½Ó¶Ô¹â·´ÉäÓë¼ä½Ó¶Ô¹â·´ÉäµÄ±íÏÖÈçºÎ£¬ÎªÊ²Ã´£¬Ç뽫¸Ã·´É侶·һһÁгö =Nj58 l
5%
E.UjC
1994 Ltt+BUJc
ird
q51{G
Ò»Ãû½â {} 11U0
1¡£Ç£ÉæÐÔÍ´ 2¡£×¶ÌåÍâϵ 3ÄÔÆÁÕÏ 0Tm"Zh?B|
FOU^Wcop%
¶þÎÊ´ð
D>c-h)2|
1¡£ÄÄЩÄÔÉñ¾Öк¬Óи±½»¸ÐÉñ¾ÏËά£¬·Ö±ðд³öËüÃǵĽÚǰÉñ¾ÔªÃû³ÆºÍλÖÃÒÔ¼°½ÚºóÏËάµÄ·Ö²¼ K&WNtk3hT
JyBsOC3
2¡£ÔÚ´óÄÔÆ¤ÖÊ»úÄܶ¨Î»ÖУ¬µÚÒ»ÇûÌåÔ˶¯ÇøÎ»Óں䦣¬ÉíÌå¸÷²¿ÔÚ´ËÇøµÄͶӰÓкÎÌØµã ]k(n_+!
A
S#D9o
3¡£ÒÀ¾ÝСÄԵĽø»¯¹ý³Ì£¬Ð¡ÄÔ¿É·Ö¼¸²¿£¬¸÷²¿µÄ·¶Î§ºÍ¹¦ÄÜÈçºÎ u,6 'yB'u
'e(
`2
4¡£¾±´ÔµÄ×é³É£¬Î»Ö㬷ֲ¼¼°¸÷Ö÷ҪƤ֧µÄÃû³ÆºÍdz³ö²¿Î» z
mxrz[
,DT=(
5¡£×ÛÊöÄÔµÄѪҺ¹©Ó¦£¬°üÀ¨Ö÷Òª·ÖÖ§µÄ·Ö²¼ºÍ´óÄÔ¶¯Âö»· W~1MeAI
jaj."v
1993 b7:B[7yK.x
:X`Bc"
Ò»Ãû½â Ij_VO{]G'l
1£¬´óÄÔ¶¯Âö»· 2¡£·´É仡 3¡£ÎÆ×´Ìå 4¡£Ð¡ÄÔÈý¶Ô½Ç 5¡£ÄÚÄÒ I<I?ks
cN> z`xl
¶þ¡£ÎÊ´ðÌâ ]byj[Gd
'M*+HY\.0
1£¬ÄÔ¼¹ÒºµÄ²úÉúºÍÑ»· 3f{%IU(z
7]q$sQ
2¡£×ó²àƤÖʺËÊøÊÜËðËùÒýÆðµÄÃæ¼¡Ì±»¾ÓëÓÒ²àÃæÉñ¾ÖÜΧÐÔËðÉËËùÒýÆðµÄÃæ¼¡Ì±»¾ÓÐÎÞÇø±ð£¬ÎªÊ²Ã´£¿ [1Dg_>lz
'y#kRC=G:
3Í«¿×¶Ô¹â·´ÉäµÄ;¾¶ kMS[
7^bO`
4ÊÖµÄÉñ¾Ö§Åä }{^i*T5rl
")U`W gx
2001Äê i6[,m*q~2x
1. ÄÔÉñ¾III¡¢VII¡¢IX¡¢XµÄÆðºË¡¢Öպˡ¢ÏËά³É·Ö¡¢Éñ¾Ðг̡¢·ÖÖ§·Ö²¼¼°¹¦ÄÜ¡£ Aa5IccR
2. ×¶ÌåϵµÄ´«Í³¸ÅÄî¼°ÐÞÕý¡£ \^wI9g~0
3. ¹¹³É×¶ÌåÍâϵµÄÖ÷Òª½á¹¹¡¢Éñ¾Í¨Â·ºÍ¹¦ÄܸÅÄî¡£ ^Slwg|t*~P
4. º£Âí½á¹¹µÄϸ°û¹¹Öþ£¬Ö÷ÒªÏËάÁªÏµºÍ±ßԵϵͳµÄ¹¦ÄÜ¡£ z,nRw/o
5. 5-HTÄÜÉñ¾ÔªÔÚÄÔÄڵķֲ¼¡¢Éñ¾Í¨Â·¡¢Ö÷ÒªÊÜÌå·ÖÐͺͶàÖÖÉñ¾¹¦ÄÜ¡£ -v9V/LJ
6. ¶à°Í°·ÄÜÉñ¾ÔªÔÚÄÔÄڵķֲ¼¡¢Éñ¾Í¨Â·¡¢ÊÜÌå·ÖÐͺ͹¦ÄÜ¡£ jZ <*XX
46'EZ@#s
Ò»¡¢ Ãû´Ê½âÊÍ n>X
1¡¢ BaylissЧӦ2¡¢WernickÄÔ²¡3¡¢WernickʧÓï4¡¢Tolosa-Hunt×ÛºÏÕ÷5¡¢Collet-Sicard×ÛºÏÕ÷ g]C+uj^
¶þ¡¢ Ìî¿Õ nTSGcMI
1¡¢ ×é³ÉѪ¹Ü×èÁ¦µÄÒòËØÓÐ_¡¢_¡¢_¡¢¼°__µÈ¡£ %ma1LN[
2¡¢ µ÷½ÚС¶¯ÂöÕÅÁ¦µÄÒòËØÓÐ_¡¢_¡¢_¼°_µÈ¡£ [IxZweK
Èý¡¢ Ñ¡ÔñÌâ Mi\f?
1¡¢ Ò»ÀýÄÐÐÔ20Ë꣬²éÌå·¢ÏÖÓÒ²à½ÇĤ·´ÉäÁéÃô£¬¼ä½Ó·´ÉäÏûʧ£¬²¡±äÔÚ EX8:B.z`57
AÓÒ²àÈý²æÉñ¾BÓҲදÑÛÉñ¾C×ó²à¶¯ÑÛÉñ¾D×ó²àÈý²æÉñ¾E×ó²àÃæÉñ¾ Dyp'a
2¡¢ Ò»ÀýÄÐÐÔ31Ë꣬1¸öÔÂÀ´×ó²àÉÏ¡¢ÏÂÖ«Âéľ£¬²éÌå·¢ÏÖÓÒ²àÃæ²¿¼°×ó²àÉÏ¡¢ÏÂÖ«Í´¾õ¼õÍË£¬²¡±ä×î¿ÉÄÜÔÚ (jCE&'?}
Aºó¸ù Bºó½Ç CÄÔ¸É DÇðÄÔ EÄÚÊø nX>k}&^L
3¡¢ Ò»ÀýÄÐ32Ë꣬¾×ÍáÀ´ÕӡÏó×ó²àÃæÉñ¾Ñ×£¬ÏÂÁÐÄĵãÕýÈ· K}O~tff
A×ó½ÇĤ·´ÉäÏûʧBÓÒÑÛíú±ÕºÏ²»È«CÕÅ¿ÚÏÂò¢Æ«Ïò½¡²àD×ó²àÃæ²¿¸Ð¾õÏûʧE×óÑÛíú±ÕºÏ²»È« WKpHb:H
4¡¢ Ò»ÀýÅ®ÐÔ50Ë꣬˫ÑÛÊÓÁ¦Ä£ºý£¬²éË«ÑÛò¨²àÆ«Òô£¬Æä²¡±ä²¿Î»ÔÚ knypSgk_
AÊÓÉñ¾ Bò¨Ò¶ C¶¥Ò¶ DÊÓÉñ¾½»²æ²¿ EÍâ²àÏ¥×´Ìå oZ%t! Fl1
5¡¢ Ò»ÀýÅ®ÐÔ35Ë꣬×óÑÛ±Õ²»½ô£¬×ó¿Ú½ÇÁ÷ÏÑ£¬×î²»¿ÉÄܵÄÖ¢×´ÊÇ
c0Jf
A×óÑÛÁ÷ÀáB×óÀáÒº·ÖÃÚ¼õÉÙC×ó²àζ¾õ¼õÍËD×ó²àÌýÉùÒô¹ýÏìEÑÀ³Ý¿Ú½Ç×óÆ« A0S6 4(
6¡¢ Ò»Àý62ËêÈË£¬Í»È»ÓÒ²àÍ·Í´£¬°éŻͣ¬BP:26/18KP£¨195/135mmHg£©ÏÂÁÐÄĸö×î²»¿ÉÄÜ -4b9(
A¶îÒ²³öѪBÄÚÄÒ³öѪCÇðÄÔ³öѪDÄÔѪ˨ÐγÉE¶¹×´ºË³öѪ v}-'L#6
7¡¢ Ò»ÀýÄÐ68Ë꣬ÕïΪ׵»ùµ×¶¯Âö¹©Ñª²»×㣬ÏÂÁÐÄÄÒ»ÖÖÊôÓڴ˲¡Ö¢×´ R\yw9!ESd
AÑ£ÔÎBÑÛÇòÔ˶¯ÕϰC½»²æÐÔÆ«DÍÌÑÊÕϰEʧÓïÖ¢ +98~OInySZ
8¡¢ Ò»Àý33ËêÅ®ÐÔ£¬¸Ðð·¢ÉÕ5Ì죬²¡ºó³öÏÖË«ÏÂÖ«ÎÞÁ¦²¢Öð½¥¼ÓÖØ£¬Æø¶Ì¡¢ÅÅÄòÀ§ÄÑ£¬²¡ºó8ÌìÀ´Õ×îÖØÒªµÄ²¡ÀíÌåÕ÷ÊÇ£º hvGb9
AË«ÏÂÖ«¼¡Á¦Ë«ÏÂÖ«¼¡Á¦I B˫ϥ·´É俺½øCºá¹ßÐԸоõÕϰDË«ÏÂÖ«²¡Àí·´ÉäÑôÐÔEÄòäóÁô x!!:jL'L
9¡¢ ͬÉÏÌ⣬×îÖØÒªµÄ¸¨Öú¼ì²éÊÇ bM8b3,}?n
AÐØ×µÏñ£¨XƬ£©BÄÔ¼¹Òº¼ì²é CÐØ×µCT D¼¡µçͼ EѪÇåÃâÒßÇòµ°°×¼ì²é >'Nrvy%&0
10¡¢ ͬÉÏÌ⣬ÄÔ¼¹ÒºÑ¹Á¦Õý³££¬°×ϸ°û20¸ö£¬µ°°×80mg%£¬ÈçºÎ´¦Àí +S|y)W8
A¾²µÎµØÈûÃ×ËÉB¼¹×µMRI C¾²µÎ¸Ê¶´¼D¾²µÎÉñ¾ÓªÑø¼ÁE¾²µÎ»·±ûɳÐÇ b#k$/A@
ËÄ¡¢ ¼ò´ðÌâ ?
_[gs/i}
1¡¢ ¶«·½È˶෢ÐÔÓ²»¯²¡Àí¸Ä±äÓëÎ÷·½ÈËÇø±ðÊÇʲô£¿ XXmtpM8
2¡¢ ƤÖÊ¡ªÎÆ×´Ì塪¼¹Ëè±äÐÔÖ÷Òª²¡Àí±ä»¯£¿ p%J,af
3¡¢ ÂýÐÔÖ²Îï״̬ÁÙ´²±íÏÖÓÐÄÄЩ£¿ s<z{ (a
4¡¢ ƫͷʹ·¢²¡»úÖÆÊÇʲô£¿ :!3CoC.X|c
5¡¢ È«ÃæÇ¿Ö±-ÕóÂη¢×÷ÖÐðïÐԻ´«²¥¾¶Â·ÊÇʲô£¿ 1NN99^q
Îå¡¢ ÎÊ´ðÌâ *;+lF
1¡¢ Alzheimer²¡Ö÷Òª²¡Àí¸Ä±äÊÇʲô? }RG
2¡¢ ÊÔÊöÖØÖ¢¼¡ÎÞÁ¦µÄ·¢²¡»úÖÆ£¿ 6E@r9U
3¡¢ Õð²üÂé±ÔÉú»¯¸Ä±äÊÇʲô£¿ &^qD<eZ!Eq
`6lc] r
> 2004ÄêÊ×Ò½Éñ¾½âÆÊÌâ 5@Ot@o
> Ò»¡¢ Ãû´Ê½âÊÍ£¨Ã¿Ìâ5·Ö£¬¹²60·Ö£© ]_|qv1K6
> 1¡¢ Ñü÷¾¸É2¡¢½Þ×´Éñ¾½Ú3¡¢¼¹Ëè½Ú¶Î4¡¢çÖºË5¡¢±ßԵϵͳ6¡¢Ç°ÄÔÄÚ²àÊø7.saphenous nerve 8.celiac plexus 9.climbing fiber 10.primary somatic motor area 11.cavernous sinus b V;R}3)
> 12. tympanic nerve u Dm=W36
> ¶þ¡¢Ñ¡ÔñÌ⣨2*15£¬1-7Ϊµ¥Ñ¡£¬8-15Ϊ¶àÑ¡£© ?KI_>{
> 1¡¢ Ö§ÅäµÚ¶þò¾×´¼¡µÄÉñ¾ÊÇ G+^HZ4jg
> A ¼¡Æ¤Éñ¾BÒ¸Éñ¾CÕýÖÐÉñ¾D³ßÉñ¾EèãÉñ¾ Sxjwqqv
> 2¡¢ Ö§ÅäÈùÏÙ·ÖÃڻµÄÉñ¾ÊÇ $0D]d.w=
> AÃæÉñ¾BÈý²æÉñ¾CÃÔ×ßÉñ¾DÉàÑÊÉñ¾E¸±Éñ¾ mWUQF"q8
> 3¡¢ ´óÄÔ´ó¾²Âö×¢ÈëµÄ½á¹¹ÊÇ cL<
AÉÏʸ״ñ¼BÏÂʸ״ñ¼Cº£Ãàñ¼DÖ±ñ¼Eñ¼»ã 5cgDHs
> 4¡¢ ÒâʶÐÔÇû¸É¡¢ËÄÖ«Éî¸Ð¾õ´«µ¼Â³µÄ½»²æ²¿Î»ÊÇ J L`n12$m
A¼¹ËèBÑÓËèCÄÔÇÅDÖÐÄÔE±³²àÇðÄÔ Z!~~6Sq
> 5¡¢ ÄÚÔà´óÉñ¾½»»»Éñ¾ÔªµÄλÖÃÊÇ W84JB3p
A×µÅÔÉñ¾½ÚB׵ǰÉñ¾½ÚCÆ÷¹ÙÅÔÉñ¾½ÚDÆ÷¹ÙÄÚÉñ¾½ÚE¼¹Éñ¾½Ú EmVE<kY.
> 6¡¢ ÓëºÚÖÊÓÐÍù·µÏËάÁªÏµµÄ½á¹¹ÊÇ VoWlBH
AÐÂÎÆ×´ÌåB¾ÉÎÅ×´ÌåCÐÓÈÊÌåDÈéÍ·ÌåEÄÚ²àÏ¥×´Ìå t~Cul+
> 7¡¢ »¼Õß²»ÄÜÓÃÉìλµÄʳָÓëÖÐÖ¸¼ÐסֽƬ£¬ÊÜËðÉ˵ÄÉñ¾ÊÇ e6
QUe.S
AèãÉñ¾ÉîÖ§BèãÉñ¾Ç³Ö§C³ßÉñ¾ÉîÖ§D³ßÉñ¾Ç³Ö§EÕýÖÐÉñ¾·µÖ§ [[Qu|?KEa
> 8¡¢ ÓÐÃÔ×ßÉñ¾²ÎÓëµÄÉñ¾´ÓÓÐ { >bw:^F
A¾±ÄÚ¶¯Âö´ÔBʳ¹Ü´ÔC·Î´ÔD¸¹Ç»´ÔEÅè´Ô 536H*HdN
> 9¡¢ Òɺ˷¢³öµÄÏËά¼ÓÈëµÄÉñ¾ÓÐAÉàÑÊÉñ¾BÃÔ×ßÉñ¾C¸±Éñ¾DÃæÉñ¾EÉàÏÂÉñ¾ j2=jD G
> 10¡¢ ÓëÉñ¾ÄÚ·ÖÃÚÓйصĺËÓÐAÊÓÉϺËBÈéÍ·ÌåºËCÊÒÅÔºËD©¶·ºËEÊÓ½»²æÉÏºË HKb8z@;%@
> 11¡¢ ²ÎÓë×é³ÉСÄÔϽŵÄÏËÎ¬ÊøÓÐA¼¹ËèСÄÔÇ°ÊøB¼¹ËèСÄÔºóÊøCéÏéСÄÔÊøDШСÄÔÊøEǰͥСÄÔÊø yFH)PQ_
> 12¡¢ ÊôÓÚÄԸɵÄÍø×´½á¹¹µÄºËÍÅÓÐAÐ¨ÊøºËBШÐκËCÐ¨Êø¸±ºËD±ÛÅÔºËEÖзìºË O9dIobu4
> 13¡¢ Ð̾¯¼¹ËèÍâ²àË÷ÄÚµÄÏËÎ¬ÊøÓÐA¼¹ËèСÄÔÇ°ÊøB¼¹ËèСÄÔºóÊøCºìºË¼¹ËèÊøDǰͥ¼¹ËèÊøE¶¥¸Ç¼¹ËèÊø NK~j>>^;v
> 14¡¢ ÊôÓÚ´óÄÔÆ¤ÖÊͶÉäÉñ¾ÔªµÄÓÐA×¶Ìåϸ°ûB¿ÅÁ£Ï¸°ûCËóÐÎϸ°ûDˮƽϸ°ûE Martinotliϸ°û }R;.~F
> 15¡¢ ¹ØÓÚÄÚ²à×ÝÊøµÄÕýÈ·ÃèÊöÓÐAÖ÷ÒªÀ´×ÔǰͥÉñ¾ºËȺBÐÐÓÚ¼¹ËèǰË÷CÏ´ïÑüËèDÖ¹ÓÚ1-4²ãÖмäÉñ¾ÔªEÍê³ÉÍ·¡¢¾±×ËÊÆ·´ÉäÐÔµ÷½Ú loLQ@?E
> Èý¡¢12*5=60·Ö 0}PW<lU-
> 1¡¢ ÊÔÊöÑÛµÄÉñ¾Ö§Å䣿 #K"jtAm
> 2¡¢ ÏÂÖ«µÄ±¾Ìå¸Ð¾õÊÇÈçºÎ´«µÝµ½´óÄÔÆ¤Öʵģ¿ 0.~QA+BD:S
> 3¡¢ ÊÔÊöÒÔϽṹÊÇÈçºÎ·Ö²ãµÄ£¿£¨1£©ÅÔÖÐÑëСҶ£¨2£©ÈÞÇò£¨3£©ÏÂÍÐ O3j:Y|N@F
> 4¡¢ ¼òÊöУַÊú뼡µÄÉñ¾Ö§Å䣨°üÀ¨Ðо¶£© .]k+hc`
> 5¡¢ ÄãÊÇÈçºÎÀí½âÇ£ÉæÐÔÍ´µÄ£¿ 1*Yf[;L
UMma|9l(i
1¡£Ò»¸öÈËÌýµ½ÌáÎÊ£¬ºó»Ø´ðÎÊÌ⣬Çëд³öËù¾¹ýµÄÉñ¾Í¨Â·£¨°´Ë³Ðò£© .Xc, Gq{
2¡£ÑÓËåºó¶¯Âö¹£ÈûȱѪ¿ÉÄÜÊÜËðµÄÉñ¾½á¹¹¼°ÆäÁÙ´²±íÏÖ¡£ 8&IsZPq%l
3¡£´ÓÉñ¾·¢Óý½Ç¶È·ÖÎö£¬ÄÔ¸ÉÉñ¾ºËÍŵķֲ¼¹æÂÉ¡£ #Ne<=ayS
¼ò´ðÌ⣺1¡£Í»´¥ 2¡£×¶ÌåÍâϵ ¡¡¡¡¡¡ SWNi@
{W)Kz_
µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ <IC=x(T
ѧ¿Æ×¨Òµ£º´«È¾²¡Ñ§ ug.mY= n'
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ O={4 >>F
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) !\'7j-6
1. ICAM-1 GLp2
?fon
2. interleukin 12(IL-12) d(3F:dbk
3. tumor infiltrating lymphocyte 8V`NQS$
4. TCR/CD3 complex h3Nwxj~E
5. hematopoietin receptor family j 6%X
6. individual idiotype(IdI) &=Gz[1
L
7. integrin "o2p|2c
8. colony-stimulatory factor (CSF) `MAee8u'
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© IL 'i7p
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? +dX1`%RR[
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ MUhC6s\F
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠQM\vruTB
4. ¼òÊö¿¹ÔÌá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ L(\sO=t
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 4EQ7OGU
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔÀí¡£ 1+~JGY#
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? r(y1^S9!8
|R8=yO%(
*%l&'+
"nP mQ
QZB2yK3]h
4:q<<vCJv
µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ k_/hgO
w$n
\`rQ
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ 5L bU'5
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ )SQ*"X4"
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© },KY9w
1. CD4 E1IRb':
2. T cell receptor(TCR) kq6S`~J^R
3. immunoglobulin superfamily (IgSF) ;>QED
4. selectin /ZqBO*]
5. anti-idiotypic antibody (¦ÁId) rUEoz |e4a
6. major histocompatibility complex(MHC) daf$`
7. immunotolerance Ja>UcE29
8. biological reponse modifier(BRM) F@Y)yi?z
9. immune reponse gene (Ir gene) -fw0bL%0
10. reshaped antibody (or reconstituted antibody) 4 d4le
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© v+U(
#"
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ^29w@*
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? 0* <gGC
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ #c@Dn.W
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? mt3j- Mw
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) Oe4 l`
=
2
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ 0JQy-hpF
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? IG0$OtG
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? f I>>w)5
s,m+q)
¡¡¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ ^0"NcOzzxl
Kdh(vNB>
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? )QE7
$|s
9 +"D8
J7
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? 4@OnMj{M
rs
{e6
¡¡ ^I3cU'X
3{RuR+yi
x3=W{Fv@4
;8/w'oe*j
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ r \H+=2E'
!R;P"%PHV
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ (Z5=GJM?$
t+Kxww
58
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Y(GH/jw
J"QXu M
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© eO;i1 >
gP8Fe =]
1. CD8 ~E-YXl9
B04%4N.g"X
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) D}'g4Ag
Ol H{!
3. immunoglobulin fold(Ig fold) j}XTa[
#%z--xuJL
4. cadherin (Ca-dependent cell adhesion moleculers) [:sP Z{
&;L4Cj$q
5. idiotype-anti-idiotypic antibody immune network theory !
Sr^4R +Z
l=D E|:
6. HLA class II antigen @QI]P{
Oh6_Bci
7. complementarity-determining region (CDR) c\FyX\i
!e@G[%k
8. perforin(or pore-forming protein ,PFP) }'$6EgX
"wL~E Si
9. high affinity IL-2 receptor 0CS^S1/[B`
`%;nHQ"
10. artificial active immunization iKv`[k
fHvQ 9*T
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© jENarB^As
wpu]{~Y
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠi,rP/A^q
u
dtsq"U_%
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 SdC505m0*
RtH[OZu(8
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ Dntcv|%u
qyl~*r*
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£
6yk
RI w6i?/I
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£)
/Z! ,1
?"+'OOqik
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ Lv,~M f1|
U#G
u
B&V
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? CvmZW$5Yo
j)Kk:BFFY
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ #W
1`vke3
~]Mq'
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ B;4hI?
%#Wg>6
¡¡ V'c9DoSRI\
5{#9b^
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ z QoMHFL3
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ \ ^EjE
]=9%fA
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ GEA@AD=^f
Bp^>R`,
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 5yp~PhHf
E1 *\)q
1. immunoglobulin gene rearrangement 9^0 'VRG
sC
]&Qr_
2. the common chain of cytokine receptor (or a cytokine receptor y>2v 9;Qp
C,]Q/6'>
subunit shared by some cytokine receptors) jR@-h"2*A
:L:;~t K
3. flow cytometry(FCM) Uvf-h4^J]:
ehxtNjA
4. carrier effect A40 -
])'!
7 bsW7;C
5. positive selection of T lymphocytes in thymus sf\;|`}
q,u>`]}
6. mouse TH1(Th1) and TH2(Th2) subsets 5F^,7A4I0
J)(]cW.
7. perforin (pore-forming protein ,PFP) 68I4 MZK>4
l*'8B)vN2
8. ADCC(antibody-dependent cell-mediated cytotoxicity) uO[4 WZ
7MGc+M(p
9. SH-2(src-homology region 2) aE,x>I 7 D
\SLYqJ~m
10. Ab2¦Â (internal image) s\7|b:y&
/cI]Z^&
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© B]*&lRR
rEAPlO.Yp
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? E\V>3rse
U#F(#3/
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? ,{oP`4\Lm
"X]ufZ7
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ;V@}
oD+
3\(s=-vh
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ .}Zmqz[
B;K{Vo:C
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠxE6y9"}!h
PTePSj1N
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) uO^{+=;A=
3_ zI$Z
ÃâÒßѧרҵ£º OOk53~2id
D 'u+3
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ a
:;*"p[R
vfy-;R(
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? hD$U8~zK
Gf%o|kX]
´«È¾²¡Ñ§×¨Òµ£º k~vmHb
t]@Zd*
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ lN1zfM
DI&xTe9k
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ qC6Q5
F
3oKqj>
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ O]PfQ
UfkRY<H
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? f0[xMn0Tu
8:A<PV!+
-p;oe}|
2;&13%@!
oqY?#p/
b%_QL3m6
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ VAthQ<
21WqLgT3 4
ÃâÒßѧÊÔÌâ $}
F]pa[
f,-|"_5;
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© AnyFg)a<
tEEhSG)s%
1. Fas(CD95)/FasL a-}%R
~XxD
[T5
2. common chain of cytokine receptor cwD0 ~B
$x)'_o}
e
3 . TCR/CD3 complex 2$Ji4`p}S
GS$k
4. negaive selection of thymocytes U-?
^B*<
n=SZ8Rj7
5. artificial active immune ,C&>mv xA
}?~uAU-
6. anti-idiotypic I L=v[)en4
c@^:tB
7. IgSF 'H'+6
Q)@1:(V/
8. Integrin |)4$\<d
< t (Pw
9. chemokine 0C p}
+{%4&T<nHw
10. B7/CD28 z-gwNE{
w.Vynb
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© ,1[??Y
`eWcp^|
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ N.G*ii\
[4hO3):F
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ u0Erz0*G4
mCt>s9a)H
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ w&"w"
h*KHEg"+
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ w~U`+2a3
8T)zB6ng
3NN'E$"3
ij i.3-
icul15'i
kxW>Da<6
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ iHn!KV
K~8tN,~&
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© n6-Ic',;
~{vdP=/WP
1. B7/CD28 "-n%874IT
EOX_[ek7
2. Th1 subset = (gmd>N
R-Q1YHUQM
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© zf,%BI[Hr
UY-IHz;&O-
4. antibody affinity maturation PGPbpl&\t
vaRwhE:
5. AP-1 LBkc s4+
A3$aMCwKd
6. single chain variable fragment£¨ScFv£© 2d2@ J{
E,LYS"%_
7. NK cell receptor U>_IYT
w2d]96*kQe
8. Zinkernagel-Doherty phenomenon oKYhE
i.t9jN
9. Ig fold 5eOj,[?
=~hsKBt*
10. CD40/CD40L ;}WtJ&y=M
?7uKP}1|
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© Fi'M"^:r{
Q)Iv_N/
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ /c@*eU
5e)6ua ,
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ y|6@-:B.
S,9NUt
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ `z}vONXpAX
f6B-~x<
l
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ {}_ Nep/;
f v E+.
{
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Dxt),4%P
rGnI( m.
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ U!&_mD#
c
[DZqCo
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ uu}`warW
)bLGEmm
x&C%4Y_]
gA~20LSt
C.J`8@a]?
PiMKu|,3
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ |[S90Gw]
4q>7OB:e
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© f64(a\Rw!^
$hkq>i \
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© >Z+"`"^o}
'yp>L|
1.Co-stimulators (or co-stimulating molecules) ;LCTCt`
vQ:wW',i
2.NK-kB D.'h?^kA
!FTNmyM~F
3.Immunoglobulin superfamily jY7=mAd
Ntb:en!X
4.antigen-presenting cell (APC) W'a(oI
TG}d3Z
U
!
5.death domain lDN"atSf
? ^M
/[@
6.CCR and CXCR &59F8JgJ
/~De2mq1
7.Lectin (or mitogen) *5_V*v6
9 Yc
n0
8.Clusters of differentiation, CD) 4({(i
oM!xz1kVL
9.B7 family nq"evD5
'+j<n[JLC
10.Cytotoxic T lymphocyte, CTL) Ko6^iI1
MJ`N,E[
11.IL-15 and IL-15 receptor (IL-15R) +#2)kg 9_
]hA,LY f
12.MHC restriction G8nrdN-9
tF*szf|$-
13.Affinity-chromatography J'b<z.OW
@@@=}!<H=
14.Cyctosprin A, CsA 7FLXx?nLY
!v|FT.
T`
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) j%L&jH6@
VIC0}LT0R
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© >@_im6
W3r?7!~
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 .~>?*}
G,f-.
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 'OkGReKt
+-<
}+8G;
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ (@r
`$5D.b
r@U3sO#N
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© :XG;ru%i
[kV;[c}
ÃâÒßѧרҵ£º oR .cSGh
SJ?6{2^
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ q5x[~]?
uR;gVO+QC
Ïû»¯ÄÚ¿Æ£º ~g#r6pzN-
#3$\Iu
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ @{hd{>K*
r%@Lej5+
ѪҺ²¡Ñ§×¨Òµ£º jN31hDg<z
y [#pC<^
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ 6$U]9D
g{IF_ 1
/E;y,o75
h `}}
*N'K/3
6;
VhL{'w7f
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ t.T
UmJ
Y;4!i?el
(רҵ»ù´¡: ÃâÒßѧ) 54lu2
gD'
gTl<wo +
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) }jH7iyjD
YB<*"HxM)}
1. ADCC(antibody dependent cell-mediated cytotoxicity) Q;11N7+
sUZX
}
2. »·æß¾úËØ(cyclosporin) [.se|]t7X
}%b;vzkG5
3. KIR(killer cell inhibitory receptor) dzLQI}89+k
[B@'kwD\l
4. HLDA(human leucocyte differentiation antigen) &Z(K6U#.
*B`Zq)
5. Interleukin 18(IL-18) j',W 64
6. ÕûºÏËØ(integrin) *eI)Z=8
7. Fas/FasL b@RHc!,>jV
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) theZ]5_C
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) GjoIm?
10. Th1/Th2 +uay(3m((
11. »ùÒòÒßÃç(DNAÒßÃç) 9T#;,{VQ
12. chemokines and chemokine receptor U*90m~)
13. ÃâÒßÄÍÊÜ V5+SWXZ
14. ¹²´Ì¼¤·Ö×Ó m/
#a0~dB
15. ËÀÍö½á¹¹Óò(death domain) UOQEk22
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) h(WrL
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? fXrXV~'8
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ_|h8q-[3
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î s4&^D<
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
+`3!I
(3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå P[s8JDqu
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ hig2
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ GfM;saTz{
(sVi\R
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) f~ }H
ÎÊ´ðÌâ(ÿÌâ25·Ö) lu Q~YjH
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ %,+leKs
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ qI^
/"k*5
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
C6rg<tCH
4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£ ^>"z@$|\:
DTW
D|M
µÚËľüÒ½´óѧһ¾Å¾Å°ËÄ격ʿѧλÑо¿ÉúÈëѧÊÔÌâ /x3/Ubmz~x
bH"hX
·Ö×ÓÉúѧ(2)¡ª¡ª×¨Òµ»ù´¡ j0@[Br %7
Z@hD(MS(C
-------------------------------------------------------------------------------- LM2TZ
fGmT_C0t
¡¡ #s!'+|2n
L~ s3b
Ò»¡¢½âÊÍÏÂÁÐÃû´Ê£¨Ã¿Ìâ5·Ö£¬¹²40·Ö£© !
!PYP'e
1. µ°°×¼¤Ã¸(protein kinase) >[X{LI(_<<
2. ÔöÇ¿×Ó(enhancer) 4DTzSy:x
3. SH2½á¹¹Óò(SH2 domain) *OQG4aWy
4. ¾ÛºÏøÁ´·´Ó¦(PCR) xLx]_R()
5. »ùÒòÖÎÁÆ(gene therapy) id$Ul?z8
6. ±äÐÔµ°°×ÖÊ(denatrued protein) ?&Pg2]
g<
7. ÐźÅëÄ(signal peptide) Q,80 Hor#J
8. cDNAÎÄ¿â ^{8Gt@
¶þ¡¢ÎÊ´ðÌâ(Ñ¡´ðËĵÀÌâ,¹²¼Æ60·Ö) `U2DkY&n
1. ʲôÊǵ°°×ÖʵÄÒ»¼¶¡¢¶þ¼¶¡¢Èý¼¶¡¢Ëļ¶½á¹¹£¿ËüÃÇÒÀ¿¿Ê²Ã´ÑùµÄÁ´ºÍÁ¦½¨Á¢ÆðÕâЩ½á¹¹£¿ËüÃÇÖ®¼äµÄ¹ØÏµÊÇʲô£¿(15·Ö) SXt{k<|
2. ¼òÊöÖØ×éDNA¼¼ÊõµÄ¶¨Òå¡¢ÔÀíºÍÖ÷Òª¹ý³Ì£¬½áºÏÄãµÄרҵ¾Ù³öÒ»¸öÓ¦Óøü¼ÊõµÄʵÀý²¢ËµÃ÷ÆäÒâÒå¡£(15·Ö) H{t_xL)k.
3. ¼òÊö°©»ùÒòÓëÒÖ°©»ùÒòµÄ¶¨Òå,¸÷¾ÙÒ»Àý˵Ã÷ÆäÔÚÖ×Áö·¢ÉúÖеÄ×÷Óá£(15·Ö) 7#wn<HDY%
4. ÒÔÈéÌDzÙ×Ý×Ó(»ò³ÆÎªÈéÌDzÙ×ÝÔª)ºÍÉ«°±Ëá²Ù×Ý×ÓΪÀý¼òÊöÔºËϸ°û»ùÒò±í´ïµ÷¿ØÔÀí¡£(15·Ö) x"~~l
5. ¼òÊöÕæºËϸ°û»ùÒò±í´ïµ÷¿ØµÄ»ù±¾»·½Ú¡¢Ö÷ÒªµÄµ÷¿Ø·Ö×Ӻ͵÷¿Ø·½Ê½¡£(15·Ö) , lJv
×¢Ò⣺ÇëÑ¡´ðËĵÀÌ⣬¶à´ðÕß¿ÛÈ¥µÃ·Ö×î¶àµÄ´ðÌ⣡£¡